Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lu AF82422 in Multiple System Atrophy (Randomized, Double-blind, Placebo-controlled with Open-label Extension)
jRCT2021240061Active, not recruiting
- Sponsor
- Lundbeck
- Start
- Jun 2025
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Randomised, double-blind trial of amlenetug in multiple system atrophy (MSA) (3 arms), sponsored by Lundbeck. Primary endpoint: Change from Baseline in UMSARS Total Score. Started Jun 2025; status: active, not recruiting.
02
Drugs
amlenetug
03
Conditions
multiple system atrophy (MSA)
Beyond the preview
Go deeper on jRCT2021240061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2021240061.